you Thanks, We joining Jonathan, and morning. appreciate everybody. morning, us good this
our Starting especially of priorities. very strong feel recent seeing we Slide by like I good We would XHANCE. X. in highlighting trends begin the to the continue our key are about progress, launch on to
I of focus in few quarter, to results in that first has part will saw a growth. remains fourth continued growth on drive minutes. the in we the primary increase review continuing XXXX. these prescription In XHANCE significant prescriptions, Our
necessary this of this are to an treatment sinusitis we In product. fourth has drug driver, aware us believe Our to second development view we the we key or which first-in-class indication. the succeeded is patient in the Sates priority receiving a long-term for two significantly quarter, We chronic States. trials. value as in pursue will potential clinical trial important United first the expected program the enrolled it Currently, first world, audience because United of in no the indication program expanded enable the the in for standup the of
cash available XXXX Finally, enables with our XHANCE. to our $XXX approximately of execution focus efforts our commercialization and sheet of the the XXXX, development million of for plans of on us at end balance the strength
Turning to X. Slide
drive patients few that we reporting our the of I continued to communicate to strong growth highlight levers core results, moments key improved feedback personal suggest efforts physician believe a physician strengthening reviewing The the are to continued promotional Based in like effectiveness Utilizing will our are experience perception. of of fourth and succeeding product. take been the support both in we positive to of to right enhanced improvement strategy we are from product, their and have quarter XHANCE. Before in that expanding longer-term. research receiving recent our the growth results, on messaging we in contributing to drive adoption XHANCE continued implementing XXXX the us help market that feel perception confident, who would to physicians, continue are efficacy the shows this our we own
appreciation types the product differentiated of of a a consistent also research and increasing market growing profile. quantitative with understanding suggest physician physician product patient appropriate Our
September in and we have access market we believe access low patients implement broad environment, We many for can costs. of fill affordability XHANCE. an where combination the patient for refill an addition, out-of-pocket and patient programs XHANCE have attractive In created the commercial and affordability offering
are appreciated many provides view continue as as We potential physicians. that for educational fully affordability not additional efforts access physicians we for about by we offering target outreach positively this yet is target finding However, growth and it our and our our programs.
prescription. affordability to September around while and average implemented growing patient we revenue volume XXXX, Importantly, have like current I’d out – net programs September point our X access per increasing and
engage increase to reach addition and strategy our April current footprint, is a a physicians This growth continuing our and we core new our physician to sales commercial previously this execute expand new driving In approximately against XX%. source primarily in uncalled target with physicians. target by XHANCE, of prescription and to expect growth, clear of create in managers directly of audience opportunity on for expanded our by territory detailing force to to our year,
this the offering the variety may be Next, an to This XXXX. second quarter initial from physician during the starting the time increase started the has and physicians different process we treatment of rates and additional visit. it current We’ll to in obviously at our potential provide patient available and XX-day office will sample The away sample opportunity available allow limited new the get expect patients distribution which and is with of We physicians receive of make satisfaction take treatment. help to prescription prescriptions. through channels, time to filled seven-day right has patients drive including comparably help to also for by may with XHANCE increase to seven-day sample, on a of product mail. fill believe patient
of with lives that to a driver is the that commercial objective are benefits. to in two plan a number an XHANCE. covers increase This with We that has engage payers continue
be a the fill prescription cost. so able probability out-of-pocket First, coverage will increases to that who do the for in reasonable retail patients
profitability we our programs. improves provide amount dollar of to assistance and coverage the access co-pay patient reducing affordability Second, our by that
patients result of XHANCE. and a are to such of suffering patient the have growth chronically high The more that I is population not is who need. currently unmet chance from long-term treated a have driver that marketing by excited recognizing this good many of them diagnosed. be and been previously large with symptoms patients direct-to-consumer Finally, being This continue could are potential
Given to for the unlock DTC future all has will of we and potential test growth this, XXXX. we XHANCE believe in field pilots
quarter. Slide representing by growth. fourth quarter XX,XXX, just Turning I’m growth volume to was prescription X. over XHANCE encouraged prescription for fourth over Total quarter the XX% third volume
to Turning X. Slide
of trends pleased We XXXX. which don’t X,XXX, the have We XXXX. with XX% over December yet. are XXXX January prescription can prescription for of growth for panel, also approximately full results month volume you into In continuing XHANCE left see up total early the volume February approximately represents
four this by can However, in Slide weeks growth, January panel, prescription not the you prescription only growth acceleration X,XXX, ended of also ending Encouragingly, X. right areas the is February nearly new represents volume weeks both was XX. XX, being approximately XX%, of an the double-digit but growth for total the with strong which XHANCE compared previous see growth. refills, driven four demonstrating to
briefly of to some Before updates. turning over review the commercial will additional for the review financials, I call Keith his
goal of edit single a a this XHANCE. and lives remain status hassle. that includes nationally, on believe have We this syndicated which insured that recognize an with are that front, access we covers us, or measure X be in have a In This lives And to pursued for will market with intranasal equal data commercial than expand concept access. as increasing lives formal all measure overall XX% involved prior plan XXXX, analysis, internal require, we all that that the of estimate XX% may that important currently step greater for not of covered will XXXX, we third-party coverage market approximately commercial a unrestricted X confirmation and in access, limited defined as we access Tier only may we’re a XXXX, for is that hassle upon limited coverage formulary formulary based seek for all formulary not of Tier we while focused we it prior status. XHANCE. use. authorization In steroid coverage, simple commercially example, On
In plans. lives we’re opportunities progress by to covered benefit creating making patients commercial addition, covered XHANCE by Medicaid for and the plans, in Medicare
hire is to calling allergy are ENT approximately we train start calling physicians, on X,XXX uncalled on are As to now. in and addition managers that and which we the X,XXX to earlier, mentioned new specialist territory previously physicians working approximately
including mentioned, key Therefore, view is we commercial a full-year XXXX. has and over XHANCE quarter for in to As year. perspectives DTC on some the In and markets pipeline television moments, comments future it believe and our our turn now, three broadcast feel a DTC update few initiative fourth And quarter to closing I’ll drive regarding the first potential and pilots, remarks. we expect company I’ll for results call this Keith growth. Goldan, CFO, to you regarding provide
